Invasive Fungal Infection Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type (Candidaemi Caa and Invasive Candiasis, Intra-abdominal Candiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Others), by Drug Type (Polyenes, Amphotericin B Deoxycholate, Lipid Formulation Amphotericin B, Others), by region, and Competition, 2020-2030F

Market Overview

Global Invasive Fungal Infection Market was valued at USD 7.55 Billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 3.75% through 2030. Invasive fungal infection refers to a serious and potentially life-threatening condition in which fungi, including yeasts and molds, penetrate and invade the tissues and organs of the body. Unlike superficial fungal infections, such as athlete's foot or ringworm, invasive fungal infections are characterized by the ability of the fungi to penetrate deep within the body, often entering the bloodstream and spreading to multiple organs. These infections typically occur in individuals with weakened or compromised immune systems, although they can affect individuals with healthy immune systems under certain circumstances. The primary risk factor for invasive fungal infections is a compromised immune system. This can result from conditions such as HIV/AIDS, cancer (especially hematological malignancies like leukemia and lymphoma), organ transplantation (due to immunosuppressive medications), long-term corticosteroid use, severe burns, and certain autoimmune diseases. Other risk factors include advanced age, malnutrition, and prolonged hospitalization.

Prompt and appropriate antifungal therapy is crucial for managing invasive fungal infections. The choice of antifungal drug depends on the type of fungus causing the infection, its susceptibility to available drugs, and the patient's clinical condition. Common antifungal classes used include azoles, echinocandins, polyenes, and flucytosine. The global aging population is more susceptible to fungal infections due to weakened immune systems and underlying health conditions. As the elderly population grows, so does the demand for antifungal treatments. Improved diagnostic methods, including molecular and biomarker-based tests, have enhanced the early detection of fungal infections. This drives the demand for timely and accurate treatments. Nosocomial (hospital-acquired) fungal infections, including candidemia, are a significant concern. Healthcare facilities are investing in infection control measures and antifungal treatments to mitigate this risk.

Key Market Drivers

Increasing Prevalence of Invasive Fungal Infections

The increasing prevalence of invasive fungal infections (IFIs) is one of the most significant drivers of the Global Invasive Fungal Infection Market. Global estimates indicate that invasive fungal infections occur annually in approximately 6.5 million cases, resulting in around 3.8 million deaths. Of these, 2.5 million deaths (68%, with a range of 35-90%) are directly attributable to the infections, highlighting the significant public health burden and the urgent need for improved prevention, diagnosis, and treatment strategies. This trend is largely attributed to several factors, including the rising number of individuals at risk due to underlying health conditions, advancements in diagnostic capabilities, and a growing awareness of fungal infections. The increasing prevalence of immunocompromised patients is a major factor contributing to the rising incidence of IFIs. Individuals with weakened immune systems such as those undergoing chemotherapy, organ transplants, or individuals with HIV/AIDS are more susceptible to fungal infections. As the global burden of chronic diseases and conditions like cancer, diabetes, and HIV continues to rise, more people are at risk of developing invasive fungal infections. Each year, over 2.1 million individuals are diagnosed with invasive aspergillosis, primarily affecting patients with chronic obstructive pulmonary disease (COPD), those in intensive care, and individuals with blood or lung cancer, with a concerning mortality rate of 85.2%. Chronic pulmonary aspergillosis impacts 1.84 million people annually, resulting in approximately 340,000 deaths, reflecting a significant mortality rate of 18.5%. Candida infections lead to nearly 1 million fatalities each year, with 1.57 million people affected globally, and a high mortality rate of 63.6%. Pneumocystis pneumonia causes over 214,000 deaths annually, affecting 505,000 individuals worldwide, with a substantial mortality rate of 42.4%. Additionally, Cryptococcal meningitis affects 194,000 individuals annually, resulting in 147,000 deaths, with a mortality rate of 75.8%. These alarming statistics underscore the severe global health impact of these fungal infections and the urgent need for enhanced prevention, treatment, and management strategies. This expanding population base directly drives the demand for targeted antifungal therapies, which is a core factor propelling market growth. Advancements in diagnostic technologies have improved the ability to detect invasive fungal infections at an early stage. Previously, fungal infections were often underdiagnosed, leading to higher mortality rates and delayed treatment. However, with the increasing prevalence of these infections, healthcare providers are now investing in faster, more accurate diagnostic tools. This has led to more frequent and earlier identification of IFIs, which in turn increases the demand for specialized antifungal drugs. Early diagnosis and subsequent treatment are crucial in managing the infection and minimizing its impact, fueling the growth of the pharmaceutical market for IFI treatments.

As invasive fungal infections become more prevalent, there is a growing need for innovative and specialized antifungal therapies. Conventional antifungal treatments, such as fluconazole and amphotericin B, may not be sufficient for treating the more severe and resistant fungal strains that are becoming more common. The rise in fungal resistance to standard therapies has led to a surge in demand for novel antifungal agents with broader spectrums of activity and fewer side effects. Pharmaceutical companies are actively developing new drugs to meet this need, contributing to the overall growth of the market. The increasing number of invasive fungal infections is also driving up healthcare costs. IFIs are often associated with prolonged hospital stays, intensive care treatments, and the need for specialized antifungal medications. As the prevalence of IFIs rises, hospitals and healthcare systems face higher costs associated with diagnosing, treating, and managing these infections. This has led to increased investments in research and healthcare infrastructure, and, in turn, further stimulates demand for antifungal medications. The economic burden of IFIs also creates opportunities for companies that develop effective and cost-efficient treatments. Invasive fungal infections, particularly in immunocompromised individuals, are often fatal if not properly managed. The growing awareness of the severe consequences associated with these infections has prompted healthcare providers to place greater emphasis on early detection and intervention. As mortality rates associated with IFIs remain a major concern, there is an urgent need for novel antifungal therapies that offer improved clinical outcomes. This demand for more effective treatments directly impacts the global market by driving investment in drug development and innovation.

As global travel becomes more frequent, the transmission of fungal pathogens across borders has become a growing concern. A recent report reveals that medical tourism to Mexico for cosmetic procedures led to a deadly fungal infection outbreak among American patients. The incident, which involved Fusarium solani meningitis, occurred at two clinics in Matamoros specializing in elective procedures such as breast augmentation, liposuction, and Brazilian butt lifts. The report, published on February 8 in the New England Journal of Medicine, detailed the cases of 13 hospitalized patients who were exposed to the F. solani fungus through epidural anesthesia administered at the River Side Surgical Center and Clinica K-3 between January 1 and May 13, 2023. This highlights the risks associated with medical tourism, especially when safety protocols are compromised. Fungal infections, particularly those caused by environmental or pathogenic fungi, can spread more easily in areas with high population mobility. This global mobility increases the number of individuals exposed to fungal pathogens, which in turn boosts the prevalence of invasive fungal infections. The higher occurrence of IFIs in both developed and developing countries further expands the market for antifungal treatments worldwide. In response to the rising prevalence of invasive fungal infections, global health organizations, including the World Health Organization (WHO), are increasingly focusing on raising awareness about the dangers of these infections. These initiatives emphasize the importance of recognizing the symptoms and the need for timely intervention. As awareness increases, both healthcare providers and the general public are more likely to seek out treatment options, contributing to greater market demand for antifungal therapies. The global aging population is another demographic factor driving the prevalence of invasive fungal infections. Older adults are particularly vulnerable to these infections due to weakened immune systems, comorbidities, and extended hospital stays. As life expectancy increases globally, the number of elderly individuals at risk of IFIs is expected to rise, thus contributing to the overall market growth for antifungal treatments.

Increasing Hospital-Acquired Infections

Hospitals and healthcare facilities are environments where patients are at an increased risk of fungal infections. Over the past five years, the World Health Organization (WHO) has conducted global surveys and joint evaluations with countries to assess the progress of national infection prevention and control (IPC) programs. A comparison of data from the 2017-18 and 2021-22 surveys reveals stagnation in the implementation of these programs, with no significant improvement in the percentage of countries having a national IPC program. In 2021-22, only four out of 106 countries (3.8%) met all the minimum IPC requirements at the national level. This lack of progress is further reflected in the inadequate implementation of IPC practices at the point of care, with only 15.2% of healthcare facilities meeting all minimum IPC standards, as reported in a 2019 WHO survey. Patients in intensive care units (ICUs), those undergoing surgeries, and individuals with catheters or central lines are particularly vulnerable. The prevalence of immunocompromised patients in hospitals further elevates the risk. Fungal infections, including Candida bloodstream infections, are often associated with the use of catheters and other medical devices. Catheter-related bloodstream infections (CRBSIs) are a significant concern in healthcare settings, and they often require antifungal treatment. The widespread use of antibiotics in hospitals can disrupt the normal microbial balance in the body, making patients more susceptible to fungal infections. This phenomenon, known as antibiotic-associated candidiasis, contributes to the demand for antifungal therapies. Patients undergoing invasive procedures, surgeries, or organ transplants may require prophylactic antifungal treatment to prevent fungal infections. This is especially true for high-risk procedures, and it drives the demand for antifungal drugs. Prolonged hospitalization can increase the risk of fungal infections, particularly in patients with weakened immune systems. Fungal pathogens can colonize patients during their hospital stay and lead to infections.

Patients in intensive care units (ICUs) are at a higher risk of developing fungal infections due to the severity of their illnesses, the use of invasive devices, and the presence of healthcare-associated pathogens. In acute-care hospitals, approximately 7 out of every 100 patients in high-income countries and 15 out of every 100 patients in low- and middle-income countries will acquire at least one healthcare-associated infection (HAI) during their hospital stay. On average, 1 in 10 of those affected by an HAI will die as a result of the infection. This underscores the critical need for enhanced infection prevention and control measures to reduce the incidence and mortality associated with HAIs globally. Hospitals are under constant pressure to implement effective infection control measures to reduce the risk of HAIs. This includes the use of antifungal agents to treat and prevent fungal infections. Improved diagnostic methods, including biomarker-based tests and molecular techniques, enable faster and more accurate identification of fungal pathogens responsible for HAIs. This leads to timely intervention and treatment. Hospitals are increasingly focused on improving patient outcomes and reducing healthcare-associated complications. Effective management of HAIs, including fungal infections, is a critical component of this effort. Healthcare regulatory bodies and accreditation organizations often have stringent requirements related to infection control and prevention in hospitals. Compliance with these requirements drives the need for antifungal therapies. This factor will pace up the demand of the Global Invasive Fungal Infection Market.

Increasing Aging Population

Aging is often associated with a natural decline in the immune system's function, known as immunosenescence. By 2030, it is projected that one in every six individuals globally will be aged 60 or older, with the population in this age group increasing from 1 billion in 2020 to 1.4 billion. By 2050, the global population of individuals aged 60 and above is expected to double, reaching 2.1 billion. Additionally, the number of individuals aged 80 or older is forecasted to triple between 2020 and 2050, rising to 426 million. This demographic shift will have significant implications for healthcare, pension systems, and workforce planning globally. This weakening of the immune response makes older individuals more susceptible to infections, including invasive fungal infections. Aging is often accompanied by the presence of chronic medical conditions such as diabetes, cardiovascular disease, and respiratory illnesses. These comorbidities can further weaken the immune system and increase the risk of fungal infections. Aging is closely associated with the increased incidence of invasive fungal diseases (IFD) such as intraabdominal candidiasis (IAC) and candidemia. The mortality rate for IFD in patients aged 65 and older rises progressively with age, with reported rates ranging from 33% to 44% among elderly patients. This underscores the critical need for targeted prevention and treatment strategies to address the growing vulnerability of this demographic to IFD-related complications. Older adults may take multiple medications to manage their health conditions, which can lead to drug interactions and adverse effects. Some medications, such as corticosteroids and immunosuppressants, can compromise the immune system and increase susceptibility to fungal infections. Older adults are more likely to reside in long-term care facilities or nursing homes, where the risk of healthcare-associated infections, including fungal infections, is elevated. Older patients often require medical procedures and surgeries for various health issues. These invasive procedures can introduce fungal pathogens and increase the risk of invasive fungal infections. The elderly population may be prescribed antibiotics more frequently, which can disrupt the balance of the body's microbiota and promote the overgrowth of fungal pathogens.

Older adults are more likely to be hospitalized, which increases their exposure to healthcare-associated fungal infections. Prolonged hospital stays can also lead to colonization by fungal pathogens. Older individuals may carry fungal pathogens asymptomatically, increasing the risk of developing invasive fungal infections when their immune systems are compromised. Older adults may present atypical or less severe symptoms of fungal infections, making diagnosis challenging. This can result in delayed treatment, which can have serious consequences. The aging population often requires specialized medical care and treatment, including antifungal therapies, to address the unique challenges associated with managing invasive fungal infections in older individuals. Many countries are experiencing a demographic shift toward an older population, creating a larger patient pool that requires healthcare services and antifungal treatments. The increased vulnerability of older adults to invasive fungal infections has drawn attention from public health organizations, leading to a focus on prevention, early diagnosis, and appropriate treatment. This factor will accelerate the demand of the Global Invasive Fungal Infection Market.

Download Free Sample Report

Key Market Challenges

Antifungal Resistance

Fungal pathogens, particularly Candida and Aspergillus species, have demonstrated the ability to develop resistance to commonly used antifungal drugs. This emergence of resistant strains can render previously effective treatments ineffective. There is a finite number of antifungal drug classes available for treating invasive fungal infections. When resistance develops to one or more drug classes within these limited options, healthcare providers face a therapeutic dilemma with fewer effective treatments to choose from. Invasive fungal infections, such as invasive candidiasis and aspergillosis, are associated with high mortality rates, especially in immunocompromised patients. Antifungal resistance can further exacerbate the risk of treatment failure and poor outcomes. Antifungal resistance can lead to prolonged hospitalizations, increased healthcare costs, and the need for more aggressive treatments. Patients may require longer periods of intensive care, adding to the overall burden on healthcare systems. Some invasive fungal infections, such as chronic pulmonary aspergillosis or fungal sinusitis, can become chronic and difficult to eradicate, especially in the presence of antifungal resistance. This may require long-term or combination therapy. In some cases, resistance to one antifungal drug can lead to cross-resistance with others in the same drug class, further limiting treatment options. The management of antifungal-resistant infections often involves the use of more expensive and less accessible antifungal drugs. This can significantly increase the overall cost of care for affected patients. Fungal resistance can be influenced by environmental factors, including agricultural practices and the use of antifungal agents in other industries. This makes resistance a complex and multifactorial issue.

Immunocompromised Patients

Immunocompromised individuals, such as those with HIV/AIDS, cancer undergoing chemotherapy, organ transplant recipients, and patients on immunosuppressive medications, are more susceptible to invasive fungal infections. Their weakened immune systems make them particularly vulnerable to fungal pathogens. The growing population of immunocompromised patients, due to factors like aging and the increasing prevalence of chronic diseases, has led to a higher incidence of invasive fungal infections. This higher incidence drives the demand for antifungal treatments. In immunocompromised patients, invasive fungal infections tend to be more severe and can progress rapidly. They often result in higher morbidity and mortality rates, making early and effective treatment crucial. Diagnosing fungal infections in immunocompromised individuals can be challenging. Their atypical clinical presentations and the need for more sensitive diagnostic methods contribute to diagnostic difficulties.

Some antifungal drugs may be less effective or more toxic in immunocompromised patients due to their compromised immune systems. This limits the choice of antifungal therapies and may require individualized treatment plans. Immunocompromised patients often require multiple medications to manage their underlying conditions. Drug interactions between antifungal agents and other medications must be carefully considered to avoid adverse effects. In certain cases, immunocompromised patients may receive prophylactic antifungal therapy to prevent fungal infections. The widespread use of prophylaxis has implications for the selection of antifungal drugs and the emergence of resistance. Immunocompromised patients may require prolonged courses of antifungal treatment, making adherence to therapy and monitoring for potential side effects critical. Managing invasive fungal infections in immunocompromised patients can be costly due to extended hospital stays, specialized care, and the use of expensive antifungal drugs. Immunocompromised patients are at a higher risk of recurrent fungal infections. This necessitates ongoing surveillance, follow-up, and potential long-term antifungal therapy.

Key Market Trends

Preventive Measures

 Prophylactic administration of antifungal drugs is increasingly employed in high-risk patient groups, such as those undergoing stem cell or solid organ transplantation and patients with hematological malignancies. Antifungal prophylaxis helps prevent fungal infections during periods of vulnerability. Healthcare organizations and professional societies have developed guidelines and recommendations for the appropriate use of antifungal prophylaxis and treatment. Adhering to these guidelines has become a standard practice to reduce the risk of invasive fungal infections. Hospitals and healthcare facilities are implementing stringent infection control measures to minimize the risk of healthcare-associated fungal infections. These practices include hand hygiene, environmental cleaning, and isolation precautions. Enhanced surveillance systems and screening protocols are in place to monitor and identify patients at risk of invasive fungal infections. Early identification allows for timely intervention and treatment. Advanced diagnostic methods, such as biomarker-based tests and molecular techniques, enable rapid and accurate identification of fungal pathogens. Early diagnosis is crucial for initiating appropriate antifungal therapy and preventing disease progression. Educating patients and their caregivers about the risks of invasive fungal infections and preventive measures, such as good hygiene and adherence to prescribed medications, is an essential component of infection prevention. Antifungal stewardship programs are being implemented in healthcare settings to ensure the appropriate and judicious use of antifungal drugs. These programs aim to prevent resistance and minimize side effects.

Segmental Insights

Disease Type Insights

In 2024, the Global Invasive Fungal Infection Market largest share was held by Candidaemi Caa and Invasive Candiasis segment and is predicted to continue expanding over the coming years. Candidemia and invasive candidiasis are among the most common forms of invasive fungal infections worldwide. Candida species are opportunistic pathogens that can cause serious bloodstream infections, especially in immunocompromised individuals and those in healthcare settings. The high incidence of these infections contributes to the market's prominence. Candidemia and invasive candidiasis can lead to life-threatening conditions, making their treatment a top priority in healthcare. These infections often require hospitalization, intensive care, and potent antifungal therapy, driving demand for effective treatments. The growing population of immunocompromised patients, such as those undergoing chemotherapy, organ transplant recipients, and individuals with HIV/AIDS, is at a heightened risk of Candida infections. As these patient populations increase, so does the need for treatment options. Candida species are often responsible for healthcare-associated infections, including catheter-related bloodstream infections. Hospitals and healthcare facilities prioritize infection control and antifungal treatments, further driving demand for therapies in this segment.

Download Free Sample Report

Regional Insights

The North America region dominates the Global Invasive Fungal Infection Market in 2024. North America, particularly the United States and Canada, boasts a highly developed healthcare infrastructure. This includes well-established healthcare facilities, advanced diagnostic capabilities, and a strong pharmaceutical industry, all of which contribute to the effective management and treatment of invasive fungal infections. The region has a relatively high prevalence of risk factors for invasive fungal infections. These risk factors include a large aging population, a high number of immunocompromised individuals (such as cancer patients and organ transplant recipients), and a substantial use of immunosuppressive drugs. These factors increase the likelihood of fungal infections and drive the demand for antifungal treatments. North America is a hub for pharmaceutical research and development. Many pharmaceutical companies and research institutions in the region are actively involved in developing new antifungal drugs and therapies. The presence of a robust research ecosystem fosters innovation and drives advancements in the field of fungal infection treatment. The United States has a well-defined regulatory framework for drug approvals through the U.S. Food and Drug Administration (FDA). The FDA's rigorous evaluation process ensures that new antifungal drugs are thoroughly tested and approved for use, which can encourage their adoption in clinical practice.

Recent Developments

• In July 2024, A USD3.98 million grant has been secured to advance the development of novel treatments for fungal diseases, with a particular focus on combating the growing global issue of antifungal drug resistance. The grant, awarded by the Medical Research Council (MRC), will support a collaborative research initiative led by Professor Elaine Bignell, Co-Director of the MRC Centre for Medical Mycology (MRC CMM) at the University of Exeter. This strategic partnership includes leading institutions such as St. George’s University Hospital in London and the University of Liverpool. The consortium, named Fungi-CARE (Combinations Against Resistance Emergence), is composed of an interdisciplinary team of scientists, clinicians, and pharmacologists working together to address the pressing challenge of antifungal resistance through innovative therapeutic combinations.
• In March 2023, GSK plc and SCYNEXIS, Inc. have recently formed an exclusive licensing agreement for Brexafemme (ibrexafungerp tablets), an FDA-approved antifungal medication designed to address vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC). Under this exclusive arrangement, GSK gains the rights to market Brexafemme for VVC and RVVC treatment while also continuing the development of ibrexafungerp. Ibrexafungerp is currently in phase III clinical trials for the potential treatment of invasive candidiasis (IC), a severe and life-threatening fungal infection. In GSK's pipeline, infectious diseases and HIV research constitute a significant portion, comprising about two-thirds. Brexafemme aligns well with GSK's portfolio of first or best-in-class treatments, which includes late-stage antibiotics such as gepotidacin, a potential groundbreaking antibiotic for uncomplicated urinary tract infections (uUTI) - the first of its kind in over two decades, and tebipenem, a promising candidate for the treatment of complicated urinary tract infections (cUTI).
• In March 2023, The U.S. Food and Drug Administration (FDA) has granted approval to rezafungin for injection, marketed as REZZAYO™, as a therapeutic option for individuals dealing with candidemia and invasive candidiasis. This groundbreaking treatment represents the first FDA-approved medication for the management of this invasive fungal infection in more than a decade. REZZAYO™ stands out as a novel antifungal therapy administered via intravenous infusion once a week. The FDA's decision to approve rezafungin for injection was founded on clinical data derived from the Phase 3 ReSTORE trial, in which Dr. Thompson took on the role of principal investigator.
• In June 2023, Applied BioCode has introduced the Fungal Panel on its BioCode® MDx-3000 system, designed exclusively for research use only (RUO) purposes. This Fungal Panel Assay was specifically developed to identify the most prevalent causative agents of invasive fungal infections (IFIs), particularly in lower respiratory samples. It can effectively detect a range of fungal agents, including Aspergillus species, Rhizopus, Mucor, Rhizomucor, Cunninghamella, Lomentospora, Fusarium, Cryptococcus, Pneumocystis jirovecii, and dimorphic pathogens such as Coccidioides immitis/posadasii, Histoplasma capsulatum, and Blastomyces dermatiditis. The panel delivers 20 distinct results in addition to an internal control and is primarily designed for utilization on the company's BioCode MDx-3000 instrument. Given the challenges in detecting IFIs, which can be slow and less sensitive through traditional culture methods, this faster and more sensitive detection approach can significantly benefit clinical management, particularly for immunocompromised patients.

Key Market Players

• Cidara Therapeutics, Inc.
• Basilea Pharmaceutica AG Allschwil
• Pfizer Inc.
• GlaxoSmith Kline
• Bayer AG
• Abbott Laboratories Ltd.
• Merck & Co, Inc.
• Astellas Pharma Inc.
• Scynexis Inc.
• Matinas BioPharma Holdings, Inc

Report Scope:

In this report, the Global Invasive Fungal Infection Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

•     Invasive Fungal Infection Market, By Disease Type:

o   Candidaemi Caa and Invasive Candiasis

o   Intra-abdominal Candiasis

o   Cryptococcal Meningitis

o   Esophageal Candidiasis

o   Histoplasmosis Acute Pulmonary

o   Others

•   Invasive Fungal Infection Market, By Drug Type:

o   Polyenes

o   Amphotericin B Deoxycholate

o   Lipid Formulation Amphotericin B

o   Others

• Invasive Fungal Infection Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Invasive Fungal Infection Market.

Available Customizations:

Global Invasive Fungal Infection Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Invasive Fungal Infection Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com